Protein detail
BCR
Breakpoint cluster region protein (EC 2.7.11.1) (Renal carcinoma antigen NY-REN-26)
Entry name BCR | UniProt ID | EVMP score 0.38 |
Frequency 1 | Transmembrane count | Protein classification Cancer-related genesDisease related genesEnzymesFDA approved drug targetsHuman disease related genesPredicted intracellular proteins |
EVMP score: annotation confidence score.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40
Basic Information
Protein Names
Breakpoint cluster region protein (EC 2.7.11.1) (Renal carcinoma antigen NY-REN-26)
Protein Class
Cancer-related genesDisease related genesEnzymesFDA approved drug targetsHuman disease related genesPredicted intracellular proteins
Protein Function
- Predicted intracellular proteins
- ENZYME proteins:Transferases
- Enzymes
- Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues
- Cancer-related genes
- Disease related genes
- FDA approved drug targets:Small molecule drugs
Ensembl
Entrez Gene Symbol
Gene Synonym
ALLBCR1CMLD22S11D22S662PHL
Gene Description
BCR activator of RhoGEF and GTPase
Chromosome
22
Position
23179704-23318037
Frequency
1
EVMP Score
0.38
Fluorescence & Localization
Tissue SpecificretinaCell SpecificCone photoreceptor cellsSingle-Nuclei Brain Specificendothelial cell
Function & Pathway
Protein Function
- Predicted intracellular proteins
- ENZYME proteins:Transferases
- Enzymes
- Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues
- Cancer-related genes
- Disease related genes
- FDA approved drug targets:Small molecule drugs
Cellular Component
Molecular Function
- GO:0004674 protein serine/threonine kinase activity
- GO:0004713 protein tyrosine kinase activity
- GO:0005085 guanyl-nucleotide exchange factor activity
- GO:0005096 GTPase activator activity
- GO:0005515 protein binding
- GO:0005524 ATP binding
- GO:0044024 histone H2AS1 kinase activity
- GO:0106310 protein serine kinase activity
Biological Process
Reactome
- R-hsa-9013148 cdc42 gtpase cycle
- R-hsa-5663202 diseases of signal transduction by growth factor receptors and second messengers
- R-hsa-1839124 fgfr1 mutant receptor activation
- R-hsa-9013149 rac1 gtpase cycle
- R-hsa-9013404 rac2 gtpase cycle
- R-hsa-9013423 rac3 gtpase cycle
- R-hsa-8980692 rhoa gtpase cycle
- R-hsa-9013026 rhob gtpase cycle
- R-hsa-9013106 rhoc gtpase cycle
- R-hsa-9012999 rho gtpase cycle
- R-hsa-1839117 signaling by cytosolic fgfr1 fusion mutants
- R-hsa-5655302 signaling by fgfr1 in disease
- R-hsa-1226099 signaling by fgfr in disease
- R-hsa-9716542 signaling by rho gtpases miro gtpases and rhobtb3
Canonical Pathways
M68 Pid rhoa reg pathway
Mediation Categories
Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediationImmune mediationMetabolism mediationReceptor-signaling mediation
Relations & Evidence
Enzyme-Mediated Modification
35 records.
| Substrate Gene Symbol | Enzyme Gene Symbol | Enzyme UniProt ID | Residue Type | Residue Offset | Modification | Database | References |
|---|---|---|---|---|---|---|---|
| BCR | GSK3B | P49841 | S | 463 | phosphorylation | KEA | KEA:17570479 |
| BCR | INSR | P06213 | Y | 246 | phosphorylation | KEA | KEA:17570479 |
| BCR | MAPK14 | Q16539 | S | 459 | phosphorylation | KEA | KEA:17570479 |
| BCR | PRKCA | P17252 | S | 1,264 | phosphorylation | KEA | KEA:17570479 |
| BCR | PRKCA | P17252 | T | 310 | phosphorylation | KEA | KEA:17570479 |
Page 4 of 4Previous
Ligand-Receptor Signaling
13 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| transmembrane | transmembrane | OmniPath | No | No | No | No | No |
| receptor | receptor | scConnect | No | Yes | No | No | No |
| transmembrane | transmembrane_predicted | Phobius | No | No | No | No | No |
Page 2 of 2Previous
Regulatory Interaction Network
9 records.
Protein Complex Composition
Sequence, Structure & Domains
Sequences
Length
1,271
Mass
142,819
Sequence
MVDPVGFAEAWKAQFPDSEPPRMELRSVGDIEQELERCKASIRRLEQEVNQERFRMIYLQTLLAKEKKSYDRQRWGFRRAAQAPDGASEPRASASRPQPAPADGADPPPAEEPEARPDGEGSPGKARPGTARRPGAAASGERDDRGPPASVAALRSNFERIRKGHGQPGADAEKPFYVNVEFHHERGLVKVNDKEVSDRISSLGSQAMQMERKKSQHGAGSSVGDASRPPYRGRSSESSCGVDGDYEDAELNPRFLKDNLIDANGGSRPPWPPLEYQPYQSIYVGGMMEGEGKGPLLRSQSTSEQEKRLTWPRRSYSPRSFEDCGGGYTPDCSSNENLTSSEEDFSSGQSSRVSPSPTTYRMFRDKSRSPSQNSQQSFDSSSPPTPQCHKRHRHCPVVVSEATIVGVRKTGQIWPNDGEGAFHGDADGSFGTPPGYGCAADRAEEQRRHQDGLPYIDDSPSSSPHLSSKGRGSRDALVSGALESTKASELDLEKGLEMRKWVLSGILASEETYLSHLEALLLPMKPLKAAATTSQPVLTSQQIETIFFKVPELYEIHKEFYDGLFPRVQQWSHQQRVGDLFQKLASQLGVYRAFVDNYGVAMEMAEKCCQANAQFAEISENLRARSNKDAKDPTTKNSLETLLYKPVDRVTRSTLVLHDLLKHTPASHPDHPLLQDALRISQNFLSSINEEITPRRQSMTVKKGEHRQLLKDSFMVELVEGARKLRHVFLFTDLLLCTKLKKQSGGKTQQYDCKWYIPLTDLSFQMVDELEAVPNIPLVPDEELDALKIKISQIKNDIQREKRANKGSKATERLKKKLSEQESLLLLMSPSMAFRVHSRNGKSYTFLISSDYERAEWRENIREQQKKCFRSFSLTSVELQMLTNSCVKLQTVHSIPLTINKEDDESPGLYGFLNVIVHSATGFKQSSNLYCTLEVDSFGYFVNKAKTRVYRDTAEPNWNEEFEIELEGSQTLRILCYEKCYNKTKIPKEDGESTDRLMGKGQVQLDPQALQDRDWQRTVIAMNGIEVKLSVKFNSREFSLKRMPSRKQTGVFGVKIAVVTKRERSKVPYIVRQCVEEIERRGMEEVGIYRVSGVATDIQALKAAFDVNNKDVSVMMSEMDVNAIAGTLKLYFRELPEPLFTDEFYPNFAEGIALSDPVAKESCMLNLLLSLPEANLLTFLFLLDHLKRVAEKEAVNKMSLHNLATVFGPTLLRPSEKESKLPANPSQPITMTDSWSLEVMSQVQVLLYFLQLEAIPAPDSKRQSILFSTEV
Alternative Products
Event=Alternative splicing; Named isoforms=2; Name=1; IsoId=P11274-1; Sequence=Displayed; Name=2; IsoId=P11274-2; Sequence=VSP_024352
Alternative Sequence
961..1004; Missing (in isoform 2)
3D Structural Models
Turn
547..549
Helix
4..14; 28..64; 492..521; 524..531; 540..546; 550..569; 578..586; 588..611; 613..618; 639..651; 653..661; 670..687; 759..761; 851..865; 876..885
Beta Strand
533..535; 630..634; 694..697; 709..719; 722..740; 751..758; 762..767; 830..838; 843..847; 1268..1271
3D Structure
NMR spectroscopy (2); X-ray crystallography (3)
Domain & Motif Annotations
Compositional Bias
87..105; Low complexity; 123..138; Low complexity; 185..198; Basic and acidic residues; 199..208; Polar residues; 346..356; Low complexity; 369..382; Low complexity; 441..451; Basic and acidic residues
Coiled Coil
28..55
Domain (CC)
The region involved in binding to ABL1 SH2-domain is rich in serine residues and needs to be Ser/Thr phosphorylated prior to SH2 binding. This region is essential for the activation of the ABL1 tyrosine kinase and transforming potential of the chimeric BCR-ABL oncogene.; DOMAIN: The DH domain is involved in interaction with CCPG1..; DOMAIN: The amino terminus contains an intrinsic kinase activity. The central Dbl homology (DH) domain functions as a guanine nucleotide exchange factor (GEF) that modulates the GTPases CDC42, RHOA and RAC1. Promotes the conversion of CDC42, RHOA and RAC1 from the GDP-bound to the GTP-bound form. The C-terminus is a Rho-GAP domain which stimulates GTP hydrolysis by RAC1, RAC2 and CDC42. The protein has a unique structure having two opposing regulatory activities toward small GTP-binding proteins.
Domain (FT)
498..691; DH; 708..866; PH; 893..1020; C2; 1054..1248; Rho-GAP
Region
1..426; Kinase; 67..173; Disordered; 185..247; Disordered; 197..385; Binding to ABL SH2-domain; 286..392; Disordered; 416..476; Disordered
Clinical Relevance
Disease Involvement
Cancer-related genesFDA approved drug targetsProto-oncogene
Drug Targets
FDA approved drug targetsPatented-recorded targetLiterature-reported targetSuccessful target
Drugs
Interaction Protein
ENSG00000108953ENSG00000141510ENSG00000164924ENSG00000204435
Interaction Count
4
Interaction Dataset
biogrid_opencellintact_biogrid